DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. Investors to Contact the Firm About Securities Fraud Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its business performance and growth prospects during the Class Period from January 8, 2024, to July 25, 2024 [1][2]. Group 1: Allegations Against DexCom - The complaint claims that DexCom's statements about growth and anticipated margins were overly optimistic, primarily due to reliance on attracting new customers [2]. - It is alleged that DexCom faced challenges in maintaining successful existing distribution channels [2]. - As a result, the statements made by DexCom regarding its business operations and future prospects were materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to apply to be appointed as a lead plaintiff representative for the class [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected DexCom investors to contact them for more information [4][5]. - The firm has a strong reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].